Prognostic role of peripheral blood lymphocyte/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: A meta-analysis

Leukemia and Lymphoma

Volumn 56, Issue 9, 2015, Pages 2563-2568

  Lin, Baochai ^a   Chen, Cuie ^a   Qian, Yan ^a   Feng, Jianhua ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Diffuse large B cell lymphoma; lymphocyte; meta analysis; monocyte; prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL;

ABSOLUTE LYMPHOCYTE COUNT ABSOLUTE MONOCYTE COUNT RATIO; ARTICLE; BLOOD CELL RATIO; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EVALUATION; DIAGNOSTIC TEST ACCURACY STUDY; EVENT FREE SURVIVAL; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MEDLINE; META ANALYSIS; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; BLOOD; DISEASE FREE SURVIVAL; LEUKOCYTE COUNT; LYMPHOCYTE; LYMPHOCYTE COUNT; LYMPHOMA, LARGE B-CELL, DIFFUSE; MONOCYTE; OUTCOME ASSESSMENT; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MONOCYTES; OUTCOME ASSESSMENT (HEALTH CARE); PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RITUXIMAB; VINCRISTINE;

EID: 84943263759     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1014367     Document Type: Article

References (39)

1. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011; 2011: 498-505.
2. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
3. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
4. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
5. Nyman H, Adde M, Karjalainen-Lindsberg ML, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109: 4930-4935.
6. Mikhaeel NG. Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now? Leuk Lymphoma 2009; 50: 1931-1936.
7. Duhrsen U, Huttmann A, Jockel KH, et al. Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas-Dhe PETAL trial. Leuk Lymphoma 2009; 50: 1757-1760.
8. Belotti A, Doni E, Bolis S, et al. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era. Clin Lymphoma Myeloma Leuk 2014 Oct 23. [Epub ahead of print]
9. Markovic O, Popovic L, Marisavljevic D, et al. Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma. Eur J Intern Med 2014; 25: 296-302.
10. Tadmor T, Bari A, Sacchi S, et al. Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre-And post-rituximab era. Haematologica 2014; 99: 125-130.
11. Porrata LF, Ristow KM, Habermann TM, et al. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma 2014; 55: 2728-2738.
12. Yan-Li L, Kang-Sheng G, Yue-Yin P, et al. The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leuk Res 2014; 38: 323-328.
13. Li YL, Gu KS, Pan YY, et al. Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. BMC Cancer 2014; 14: 341.
14. Prochazka V, Pytlik R, Janikova A, et al. A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent. PLoS One 2014; 9: e102594.
15. Koh YW, Park CS, Yoon DH, et al. Should the cut-off values of the lymphocyte to monocyte ratio for prediction of prognosis in diffuse large B-cell lymphoma be changed in elderly patients? Eur J Haematol 2014; 93: 340-348.
16. Wei X, Huang F, Wei Y, et al. Low lymphocyte-Do-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma. Leuk Res 2014; 38: 694-698.
17. Li YL, Pan YY, Jiao Y, et al. Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens. Ann Hematol 2014; 93: 617-626.
18. Rambaldi A, Boschini C, Gritti G, et al. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. Am J Hematol 2013; 88: 1062-1067.
19. Li ZM, Huang JJ, Xia Y, et al. Blood lymphocyte-Do-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One 2012; 7: e41658.
20. Watanabe R, Tomita N, Itabashi M, et al. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era. Eur J Haematol 2014; 92: 204-210.
21. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-Analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
22. Hotta K, Matsuo K, Ueoka H, et al. Meta-Analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 3852-3859.
23. DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
24. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
25. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-Analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
26. Kim DH, Baek JH, Chae YS, et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 2007; 21: 2227-2230.
27. Cox MC, Nofroni I, Laverde G, et al. Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 265-268.
28. Feng J, Wang Z, Guo X, et al. Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma: a meta-Analysis. Int J Hematol 2012; 95: 143-148.
29. Wilcox RA, Ristow K, Habermann TM, et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 2011; 25: 1502-1509.
30. Porrata LF, Ristow K, Habermann TM, et al. Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma. Leuk Lymphoma 2012; 53: 2159-2165.
31. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010; 47: 115-123.
32. Novak AJ, Grote DM, Stenson M, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004; 104: 2247-2253.
33. Oki Y, Georgakis GV, Migone TS, et al. Elevated serum BLyS levels in patients with non-Hodgkin lymphoma. Leuk Lymphoma 2007; 48: 1869-1871.
34. Shivakumar L, Ansell S. Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies. Clin Lymphoma Myeloma 2006; 7: 106-108.
35. Dirkx AE, Oude Egbrink MG, Wagstaff J, et al. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 2006; 80: 1183-1196.
36. De Palma M, Naldini L. Tie2-expressing monocytes (TEMs): novel targets and vehicles of anticancer therapy? Biochim Biophys Acta 2009; 1796: 5-10.
37. Dehghani M, Sharifpour S, Amirghofran Z, et al. Prognostic significance of T cell subsets in peripheral blood of B cell non-Hodgkin's lymphoma patients. Med Oncol 2012; 29: 2364-2371.
38. Gergely L, Vancsa A, Miltenyi Z, et al. Pretreatment T lymphocyte numbers are contributing to the prognostic significance of absolute lymphocyte numbers in B-cell non-Hodgkins lymphomas. Pathol Oncol Res 2011; 17: 249-255.
39. Wada N, Zaki MA, Hori Y, et al. Tumour-Associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. Histopathology 2012; 60: 313-319.